PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Infections Drop As study Backs Long AstraZeneca Jab Dose Interval

Fri, 19th Feb 2021 16:44

(Alliance News) - Coronavirus infections are dropping across the UK, new data suggests, as a study found that giving doses of the Oxford/AstraZeneca PLC vaccine 12 weeks apart improves protection.

Around one in 115 people in private households in England had Covid-19 between February 6 and 12, the Office for National Statistics (ONS) said, down from around one in 80 people from January 31 to February 6.

Meanwhile, in Wales, around one in 125 people are estimated to have had Covid-19 between February 6 and 12, down from one in 85 previously.

In Northern Ireland, the figure is around one in 105 people, down from one in 75, while in Scotland it is around one in 180 people, down from one in 150.

The data, which does not cover care homes and hospitals, is based on swab tests from thousands of people regardless of whether or not they have symptoms.

It comes as new analysis from Oxford University published in The Lancet confirmed that a single dose of the AstraZeneca vaccine offers 76% protection against Covid-19 from 22 days after vaccination, and that this had not waned by the three-month mark.

The UK policy of leaving up to 12 weeks between doses also resulted in a higher efficacy overall, the study found.

There was 81% protection when three months was left between the two doses, compared to 55% for up to a six-week interval.

The Oxford team is still urging people to have two doses of the vaccine because they say it is not yet clear how long protection with a single dose may last.

Meanwhile, government scientists put the R – the number of people an infected person will pass coronavirus on to – at 0.6 to 0.9 for the UK, compared to 0.7 to 0.9 in the previous week.

The lower end estimate is at its lowest point recorded by the scientists, and the R is below 1 in all regions of England.

However, the experts warned that "prevalence of the virus remains high, so it remains vital that everyone continues to stay at home in order to keep the R value down".

Earlier, top scientific advisers said vaccines were having an impact on the pandemic, as Prime Minister Boris Johnson prepares to publish his road map out of lockdown on Monday.

Professor Adam Finn, from the University of Bristol and a member of the Joint Committee on Vaccination and Immunisation (JCVI), said "everything's moving in the right direction" when it comes to how jabs are working.

He told BBC Radio 4's Today programme: "We've now got to the point with the study we're doing in Bristol where we can say with certainty that there is definitely an effect.

"It's just hard to put an exact number on it at this point because… the numbers of cases coming through are still building up, the number of people who've been vaccinated are still going up, but it's becoming clearer for the Pfizer Inc vaccine, which we've been using for a month longer, since early December, and it'll take slightly longer for us to get a firm handle on just how well the AstraZeneca vaccine is preventing hospitalisations too, but they're definitely doing the job."

Professor Neil Ferguson, from Imperial College London, said the data on vaccine effectiveness and how quickly infection, deaths and hospital cases were declining across the country was looking promising.

He said he thought the current lockdown should be lifted in stages, adding: "I am encouraged by the cautious approach being taken, an incremental approach which I think will be adopted, namely relax one thing and see what the impact is, relax again.

"And it still may well be that by the end of May, we're in a very different country than we are today."

Figures show a continued decline since Christmas in the number of new cases of coronavirus, although rates vary according to region.

Overall, 74,961 new cases were recorded in England in the seven days to February 14, the equivalent of 133.2 per 100,000 people.

This is down sharply from a peak of 680.8 cases per 100,000 people on January 4.

It is also the lowest seven-day rate since October 4.

Meanwhile, the number of patients in hospital in England with Covid-19 has also fallen sharply in recent weeks.

A total of 15,633 patients were in hospital as of 8am on February 18, down 54% from a record 34,336 patients exactly one month earlier.

But while this is a sizeable drop, numbers at both a national and regional level are still higher than when England came out of its second lockdown on December 2.

All regions also continue to report patient numbers well above those seen last May, when Boris Johnson announced the initial easing of the first lockdown.

Meanwhile the number of daily hospital admissions of patients with Covid-19 stood at 1,311 on February 16, down 68% from a peak of 4,134 on January 12, but still above the 1,262 on the day England came out of its second lockdown on December 2.

Elsewhere, Wales' First Minister Mark Drakeford has said some aspects of non-essential retail, as well as personal services such as hairdressing, could begin to reopen there from March 15, with stay-at-home restrictions eased in three weeks.

All primary school children in Wales are expected to return to face-to-face teaching from mid-March, while the number of people allowed to exercise together will increase from two to four.

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.